Chemoimmunotherapy plus targeted radiation before surgery for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of chemotherapy, immunotherapy, and a type of radiation that avoids nearby lymph nodes, given before surgery for a specific stage of esophageal cancer. The goal is to see if this approach can improve outcomes and make surgery more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of esophageal cancer called squamous cell carcinoma, confirmed by biopsy.
- You have not had any prior treatment for esophageal cancer, such as chemotherapy, radiation, or surgery.
- Your cancer is stage T3N+M0, meaning it has grown into the outer layer of the esophagus and may have spread to nearby lymph nodes, but not to distant organs.
- You are between 18 and 75 years old.
- You are in good overall health, with a performance status score of 0 or 1, meaning you can carry out daily activities without significant limitation.
- You are willing to undergo surgery after the neoadjuvant (pre-surgery) treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving chemotherapy and radiation before surgery, followed by immunotherapy, can improve outcomes for people with a specific type of esophageal cancer that can be surgically removed.
This trial compares adding immunotherapy to standard chemo-radiation before surgery for locally advanced, operable esophageal squamous cell cancer. It aims to improve how well the tumor responds and whether patients do better after surgery.
This trial tests giving a combination of chemotherapy, radiation therapy, and an immunotherapy drug before surgery for a type of esophageal cancer (squamous cell). The goal is to see if this approach helps shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
This trial tests whether giving tislelizumab (an immunotherapy) along with chemotherapy before and after surgery can help people with a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this combination improves outcomes for patients whose cancer is in the chest and can be removed with surgery.
This trial tests combining a type of immunotherapy (adebrelimab) with chemotherapy before surgery, for esophageal cancer that can be removed. The goal is to see if this combo helps shrink the tumor and improve outcomes.
This study tests a new immunotherapy drug (tislelizumab) combined with chemotherapy before either surgery or radiation for esophageal cancer. The goal is to see if this combination helps shrink the tumor and improves outcomes, and it may offer a promising option for patients who meet the criteria.
Hear when a new Esophageal Cancer Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.